Source: Jnci-journal of the national cancer institute. Unidade: FM
Subjects: ANTINEOPLÁSICOS, METÁSTASE NEOPLÁSICA, NEOPLASIAS COLORRETAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OVERMAN, Michael J. e HOFF, Paulo M. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. Jnci-journal of the national cancer institute, v. 110, n. 8, p. 888-894, 2018Tradução . . Disponível em: https://doi.org/10.1093/jnci/djx288. Acesso em: 07 nov. 2024.APA
Overman, M. J., & Hoff, P. M. (2018). The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. Jnci-journal of the national cancer institute, 110( 8), 888-894. doi:10.1093/jnci/djx288NLM
Overman MJ, Hoff PM. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia [Internet]. Jnci-journal of the national cancer institute. 2018 ; 110( 8): 888-894.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1093/jnci/djx288Vancouver
Overman MJ, Hoff PM. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia [Internet]. Jnci-journal of the national cancer institute. 2018 ; 110( 8): 888-894.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1093/jnci/djx288
